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In this study, 275 patients in use of tenofovir were retrospectively followed-up for three
years to evaluate risk factors involved in impaired renal function. Analysis of variance
(ANOVA) and Tukey’s test were used to verify any differences in creatinine levels and esti-
mated clearance at 0, 6, 12, 24 and 36 months, adjusting for the co-variables sex, skin
color, age >50 years, arterial hypertension, diabetes and the use of the ritonavir-boosted
protease inhibitors (PI/r) lopinavir/r or atazanavir/r. The software package STATISTICA 10®
was used for statistical analysis. The patients’ mean age was 43.2 ± 10.7 years. Systemic
arterial hypertension (SAH) and diabetes were found in 20.4% and 8.7% of the patients,
respectively. Overall, 96.7% were on tenofovir associated with lamivudine (TDF + 3TC), 39.3%
on  lopinavir/r, 29.8% on efavirenz, and 17.6% on atazanavir/r. There was  a statistically sig-niﬁcant difference in estimated creatinine clearance at 24 months, when the co-variables
male  (F = 3.95; p = 0.048), SAH (F = 6.964; p = 0.009), and age over 50 years (F = 45.81; p < 0.001)
were taken into consideration. Analysis of the co-variable use of atazanavir/r showed a
tendency toward an increased risk over time (F = 2.437; p = 0.063); however, no signiﬁcant
time  interaction was seen. At 36-month, a statistically signiﬁcant difference was found for∗ Corresponding author.
E-mail address: lauro.neto@emescam.br (L.F.d.S. Pinto Neto).
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age over 50 years, (F = 32.02; p < 0.05) and there was a signiﬁcant time-by-sex interaction
(F  = 3.117; p = 0.0149). TDF was discontinued in 12 patients, one because of a femoral neck
fracture (0.7%) and 11 due to nephrotoxicity (4%). Of these latter cases, 9/11 patients were
also using protease inhibitors. These data strongly alert that tenofovir use should be indi-
vidualized with careful attention to renal function especially in male patients, over 50 years,
with  SAH, and probably those on ATV/r.
© 2015 Elsevier Editora Ltda. All rights reserved.
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or years now, antiretroviral therapy (ART) has been chang-
ng the natural history of the human immunodeﬁciency virus
HIV) infection by reducing its related morbidity and mortal-
ty, resulting in high survival rates among infected patients.1,2
owever, new adverse effects have arisen, with an impor-
ant impact on patients’ quality of life such as progressive
hanges in renal function apparently related to the use of
enofovir (TDF).3 Initiating ART with TDF as a component of
 dual-nucleoside analog regimen is already a consensus in
he literature due to its potency, good tolerability proﬁle and,
ainly, to its low pill burden regimen and co-formulations.4–6
hese features increase in importance considering the current
ontext of treating all patients at an early stage,4,5 thus expos-
ng patients to the use of antiretroviral (ARV) therapy for longer
eriods of time and to the consequent cumulative toxicity,7
ithout, however, taking into account individual factors that
ay be associated with greater probability of developing side
ffects. Another important fact is that TDF is the approved
rug for pre-exposure prophylaxis (PrEP),4,6 thereby also gen-
rating risks for patients who are not infected with HIV. The
bjective of the present study was to evaluate the risk fac-
ors for developing impaired renal function in patients in use
f TDF who  were receiving care at an AIDS reference center
n Vitória, Espírito Santo, Brazil between April 2006 and April
013.
aterial  and  methods
atients infected by HIV [either mono-infected or co-infected
ith the hepatitis B virus (HBV) or with the hepatitis C virus
HCV)] and HBV mono-infected patients, at the outpatient HIV
linic at Santa Casa de Vitoria, ES, all of whom in use of TDF
etween April 2006 and April 2013, were included in the study.
his outpatient clinic is an important reference center in the
tate of Espirito Santo, taking care of around 900 individuals.
or inclusion in the study, patients’ records should have infor-
ation about the urine analyses, creatinine measurements
nd estimated clearance calculated according to the Chronic
idney Disease Epidemiology Collaboration (CKD-EPI) equa-
ion, prior to treatment and at 6 months, 1 year, 2 years, and
 years of follow-up. A total of 275 patients were screened as
hey had at least one measure before initiating TDF and one
easure after that. As AZT/3TC was the ART backbone rec-mmended by National Guidelines at that time, almost 30%
f the patients were using TDF. Of those on TDF, 21 patients
ere excluded, as no measures before use were available. TheCKD-EPI was chosen because it is more  frequently used to eval-
uate renal function in HIV patients.8 An Excel database was
created and repeated measures analysis of variance (ANOVA)
was used to check for any changes in renal function at 6, 12, 24,
and 36 months adjusting for the co-variables sex, skin color,
diabetes, systemic arterial hypertension (SAH), age, and use
of the ritonavir-boosted protease inhibitors (PI/r), atazanavir/r
or lopinavir/r. Repeated-measures ANOVA is an extension of
the paired-t test that is required for comparing three or more
dependent means. It is used when variables are measured at
multiple times in the same subject to assess changes due to an
intervention. Tukey’s test was used whenever any difference
was found. The software STATISTICA 10® was used for statis-
tical analysis. The signiﬁcance level adopted for the study was
5%.
Results
Of the 275 participants in the study, 176 (64%) were white,
171 were male (62%). The mean age was 43.2 ± 10.7 years.
Overall, 253 were HIV-mono-infected patients, while 10 were
co-infected with HBV, 5 with HCV, and 7 were HBV-mono-
infected. HIV risk factor was heterosexual relation in 172
cases, while 77 cases consisted of men  who  had sex with
men (MSM), and 12 patients were injection drug users (IDU).
Overall, 20.4% had SAH. Fasting glucose levels were abnormal
in 14.9%, with 8.7% being diabetics (Table 1). The asso-
ciation of TDF with lamivudine (TDF + 3TC) was used by
96.7%. Lopinavir/r was used by 39.3% of patients, efavirenz
(EFV) by 29.8%, and atazanavir/r by 17.6%, while 6.9% used
another PI/r, and 4.6% of the patients were on nevirap-
ine. At baseline, mean estimated glomerular ﬁltration rate
(eGFR) was 100.5 ± 17.66 mL/min (n = 275 patients). Mean eGFR
decreased to 96.15 ± 23.15 mL/min at six months (measured
in 244 patients, 61.5% male), 94.5 ± 20.74 mL/min at one year
(measured in 247 patients, 62.3% male), 92.18 ± 22.42 mL/min
at two years (measured in 227 patients, 62.6% male), and
89.80 ± 21.1 mL/min at three years of follow-up (measured in
170 patients, 63.5% male). Proteinuria was detected, using test
strips, in 1.1% of patients at baseline, 2.5% at six months, in
3% at one year, and in 5% at two and three years of follow-up.
At the 24-month analysis, statistically signiﬁcant differences
were found over time in patients’ creatinine levels and clear-
ance (p < 0.05). Male sex (F = 3.95; p = 0.048), presence of SAH
(F = 6.964; p = 0.009), and age over 50 years (F = 45.81; p < 0.001)
were statistically associated with greater decrease in esti-
mated clearance levels. In addition, there was a trend toward
renal function deterioration among those on atazanavir/r
(F = 2.437; p = 0.064) (Table 2 and Fig. 1). Furthermore, the
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Table 1 – Characteristics of HIV mono-infected patients
and co-infected with HBV or with HCV at the outpatient
HIV clinic at Santa Casa de Vitoria, ES, 2006–2013.
N◦ %
Sex
Male 171 62.2
Female 104 37.8
Skin color
White 98 35.6
No white 176 64.0
Missing 1 0.4
Age
20–30 23 8.4
30–40 84 30.5
40–50 91 33.1
50–60 53 19.3
Over 60 24  8.7
Risk factor for HIV infection
Heterosexual 171 62.2
MSMa 77 28.0
IDUb 12 4.4
Transfusion 2 0.7
Unknown 13 4.7
Arterial hypertension 56 20.4
Diabetes 24 8.7
a Men who made sex with men.
b Injection drug users.
Table 2 – Repeated measures analysis of variance
(ANOVA) comparing estimated creatinine clearance
(CKD-EPI) evolution in time to male sex, skin color,
diabetes, use of PI/r, use of atazanavir, SAH, and age
over 50 s.
Time ≤24 months P-value
Factors F
Time 10.859 0.000
Male sex 3.950 0.048
Time-by-sex 2.223 0.084
Time 14.772 0.000
Skin color 0.387 0.535
Time-by-skin color 2.201 0.087
Time 9.719 0.000
Diabetes 0.812 0.369
Time-by-diabetes 1.851 0.137
Time 12.405 0.000
PI/r 0.086 0.769
Time-by-PI/r 0.725 0.537
Time 12.495 0.000
Atazanavir 3.199 0.075
Time-by-atazanavir 2.437 0.064
Time 13.180 0.000
SAH 6.964 0.009
Time-by-SAH 0.894 0.444
Time 15.542 0.000
Age > 50 45.814 0.000
Time-by-age 2.183 0.089
Values in bold show p < 0.05.
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Fig. 1 – 24 months follow-up of Creatinine Clearance
(CKD-Epi) in patients stratiﬁed by ATV/r use.
time-by-skin color interaction showed a tendency toward a
decrease in the estimated creatinine clearance in non-white
individuals (F = 2.201; p < 0.087). However, there was no sig-
niﬁcant time interaction effect for any of the co-variables
evaluated at 24 months. At 36-month, age over 50 years was
the only co-variable associated with signiﬁcant decrease in
the estimated creatinine clearance (F = 32.020; p < 0.05), with
time-by-sex interaction (F = 3.117; p = 0.015) also being statisti-
cally signiﬁcant. Tukey’s test showed a signiﬁcant difference
in impaired renal function in men  (Table 3). The drug had
to be discontinued in 12 patients, 11 because of nephrotox-
icity, characterized by eGFR <60 mL/min and/or proteinuria
(4%), and one because of a femoral neck fracture (0.7%). Of
the 11 patients whose treatment was discontinued because of
nephrotoxicity, nine were also using PIs.
Discussion
After 36 months of TDF use, patients in the present study suf-
fered signiﬁcant impairment of renal function that worsened
over time. Scherzer et al. followed up a large cohort of HIV-
infected US veterans comparing individuals who  had been
exposed to TDF over a 5-year period with controls who had
not. Those investigators reported progression to chronic kid-
ney disease in 7.7% of those who had been on TDF compared to
3.8% of those who had not.9 In the D:A:D study, the cumulative
use of TDF and atazanavir/r was found to be an independent
predictor of eGFR <70 mL/min, while an eGFR in the range of
60–70 mL/min was also associated with a higher rate of dis-
continuation of TDF.10 The present study also indicates a trend
toward a reduction in the eGFR with atazanavir/r and discon-
tinuation of TDF with an eGFR <60 mL/min. A metanalysis of 17
studies involving 10,889 patients followed up for a mean of 48
weeks showed that regimens with TDF were associated with
greater renal function impairment compared to regimens that
did not include TDF – a mean difference in eGFR of 3.92 mL/min
7(Cockroft-Gault formula; 95% CI: 2.13–5.7 mL/min). A retro-
spective cohort study conducted by the Kaiser Permanente
Medical Care Program in the United States showed that even
small changes in the glomerular ﬁltration rate in absolute
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Table 3 – Tukey’s test for multiple analysis for creatinine clearance (CKD-EPI) and time-by-sex interaction.
Sex Time (months) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10}
Male 0 0.331 0.002 0.000 0.000 0.814 0.994 0.465 0.498 0.442
Male 6 0.331 0.792 0.196 0.000 1.000 1.000 0.994 0.996 0.992
Male 12 0.002 0.792 0.995 0.166 1.000 0.984 1.000 1.000 1.000
Male 24 0.000 0.196 0.995 0.749 0.997 0.854 1.000 1.000 1.000
Male 36 0.000 0.000 0.166 0.749 0.735 0.272 0.958 0.948 0.965
Female 0 0.814 1.000 1.000 0.997 0.735 0.992 0.999 1.000 0.999
Female 6 0.994 1.000 0.984 0.854 0.272 0.992 0.761 0.800 0.731
Female 12 0.465 0.994 1.000 1.000 0.958 0.999 0.761 1.000 1.000
Female 24 0.498 0.996 1.000 1.000 0.948 1.000 0.800 1.000 1.000
Female 36 0.442 0.992 1.000 1.000 0.965 0.999 0.731 1.000 1.000
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Tenofovir Diproxil Fumarate in HIV-infected patients. ClinValues in bold show p < 0.05.
erms tend to persist and intensify over time.11 A study con-
ucted with a French cohort also showed that exposure to TDF
as associated with more  chronic kidney disease, particularly
hen administered together with PIs (incidence rate ratio: 3.0
ith PIs and 1.3 without PIs; p < 0.001).12 Even when admin-
stered for a short time in pre-exposure prophylaxis (PrEP), a
igniﬁcant decrease in the glomerular ﬁltration rate was found
fter a four-week exposure to TDF associated with emtric-
tabine (TDF/FTC) in 2499 HIV-negative patients included in
 randomized, placebo-controlled study (−2.4 mL/min versus
1.1 mL/min; p = 0.02, respectively).13
SAH and age >50 years were factors signiﬁcantly associ-
ted with renal function impairment in the present study.
ndeed, SAH and age are classic risk factors for deterioration in
enal function in the general population.14 This research group
as already reported that SAH and age >50 years were risk
actors for decreased renal function in HIV-positive patients
n the Brazilian state of Espírito Santo.15 A cross-sectional
tudy with 255 patients receiving care at an outpatient clinic
n Porto Alegre detected SAH, exposure to TDF, and duration
f antiretroviral treatment as risk factors for chronic kidney
isease.16 Another cross-sectional study conducted in Rio de
aneiro also associated SAH and exposure to TDF in addi-
ion to diabetes and age >50 years as risk factors for eGFR
60 mL/min.17 To the best of our knowledge, the present study
s the ﬁrst longitudinal study in Brazil to show progressive loss
f renal function, aggravated in a cumulative manner by the
uration of exposure to TDF.
In the present cohort, being male was a risk factor for a
ecrease in eGFR at 36 months of follow-up. We were unable
o ﬁnd any other studies in the literature that supported this
nding. Some publications have indicated that being female
hould be a risk factor for chronic kidney disease, with lower
uscle mass being one of the possible explanations for these
ndings; however, there was no association with the use of
DF speciﬁcally.12 In a study involving only women receiv-
ng pre-exposure prophylaxis (PrEP), the only difference found
etween the patients using TDF/FTC orally compared to the
se of 1% TDF gel was an increase in creatinine levels (1.3% ver-
us 0.2% p = 0.004). Nevertheless, there was no other relevant
ide effect.18
There are limitations associated with the present study,
articularly because it consists of a retrospective analysis of
ata from patient charts, without a control group of individ-
als not using TDF. Unfortunately a control group was notfeasible, because very few creatinine measures were avail-
able for patients on zidovudine, not in sufﬁcient number to
compare with patients on TDF. Nevertheless, since the study
population is relatively young, the nephrotoxic effect with pro-
longed use in males, particularly those over 50 years of age
and with comorbidities such as SAH, is an important ﬁnd-
ing. The association with PIs, particularly the tendency to
develop nephrotoxicity when atazanavir/r is associated, has
been shown in other studies. Widespread treatment with the
new co-formulation TDF/3TC/EFV in Brazil, together with the
aging of the Brazilian population infected by HIV, demands
greater care in monitoring kidney function.
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